BJ-005 for Solid Tumor or Lymphoma
This trial will study the safety and feasibility of a new drug, BJ-005, in patients with advanced cancer. The drug is a bifunctional molecule that targets the protein PD-L1.
- Advanced Solid Tumor or Lymphoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is this research endeavor actively enrolling new participants?
"As indicated on clinicaltrials.gov, this medical trial is currently accepting participants. The initial post was published October 20th 2021 and the latest update occurred July 19th 2022."
How perilous is BJ-005 for human subjects?
"Due to the limited clinical data available, BJ-005 was given a score of 1 for safety. As this is only a phase one trial there are minimal studies attesting to its efficacy and safety."
How many healthcare centers are implementing this investigation?
"For this trial, patients can receive treatment at the Mayo Clinic in Florida and Arizona, as well as Hematology/Oncology Assoc. of the Treasure Coast located in North Carolina. Additionally, 6 other locations are currently involved with this study."
How many people have volunteered to participate in this trial thus far?
"This medical trial requires 85 eligible patients, who fit the inclusionary criteria, to register. Participants may come from either Mayo Clinic - Florida (Jacksonville) or Mayo Clinic - Phoenix (Phoenix)."